Single MHC-I Expression Promotes Virus-Induced Liver Immunopathology.
Journal
Hepatology communications
ISSN: 2471-254X
Titre abrégé: Hepatol Commun
Pays: United States
ID NLM: 101695860
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
pubmed:
16
2
2022
medline:
29
6
2022
entrez:
15
2
2022
Statut:
ppublish
Résumé
Major histocompatibility complex I (MHC-I) molecules present epitopes on the cellular surface of antigen-presenting cells to prime cytotoxic clusters of differentiation 8 (CD8)
Identifiants
pubmed: 35166071
doi: 10.1002/hep4.1913
pmc: PMC9234681
pii: 02009842-202207000-00012
doi:
Substances chimiques
Epitopes
0
Histocompatibility Antigens
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1620-1633Informations de copyright
© 2022 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.
Références
Protzer U, Maini MK, Knolle PA. Living in the liver: hepatic infections. Nat Rev Immunol 2012;12:201‐213.
Bechmann LP, Hannivoort RA, Gerken G, Hotamisligil GS, Trauner M, Canbay A. The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol 2012;56:952‐964.
Reinke H, Asher G. Circadian clock control of liver metabolic functions. Gastroenterology 2016;150:574‐580.
Macpherson AJ, Heikenwalder M, Ganal‐Vonarburg SC. The liver at the nexus of host‐microbial interactions. Cell Host Microbe 2016;20:561‐571.
Rehermann B. Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med 2013;19:859‐868.
Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005;5:215‐229.
Knolle PA. Staying local‐antigen presentation in the liver. Curr Opin Immunol 2016;40:36‐42.
Huang L‐R, Wohlleber D, Reisinger F, Jenne CN, Cheng R‐L, Abdullah Z, et al. Intrahepatic myeloid‐cell aggregates enable local proliferation of CD8(+) T cells and successful immunotherapy against chronic viral liver infection. Nat Immunol 2013;14:574‐583.
Benseler V, Warren A, Vo M, Holz LE, Tay SS, Le Couteur DG, et al. Hepatocyte entry leads to degradation of autoreactive CD8 T cells. Proc Natl Acad Sci U S A 2011;108:16735‐16740.
Böttcher J, Schanz O, Wohlleber D, Abdullah Z, Debey‐Pascher S, Staratschek‐Jox A, et al. Liver‐primed memory T cells generated under noninflammatory conditions provide anti‐infectious immunity. Cell Rep 2013;3:779‐795.
Mueller SN, Ahmed R. High antigen levels are the cause of T cell exhaustion during chronic viral infection. Proc Natl Acad Sci U S A 2009;106:8623‐8628.
Moskophidis D, Lechner F, Pircher H, Zinkernagel RM. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 1993;362:758‐761.
McDevitt HO. Discovering the role of the major histocompatibility complex in the immune response. Annu Rev Immunol 2000;18:1‐17.
Singh R, Kaul R, Kaul A, Khan K. A comparative review of HLA associations with hepatitis B and C viral infections across global populations. World J Gastroenterol 2007;13:1770‐1787.
Thursz MR, Thomas HC, Greenwood BM, Hill AV. Heterozygote advantage for HLA class‐II type in hepatitis B virus infection. Nat Genet 1997;17:11‐12.
Hraber P, Kuiken C, Yusim K. Evidence for human leukocyte antigen heterozygote advantage against hepatitis C virus infection. Hepatology 2007;46:1713‐1721.
Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, Goedert JJ, et al. HLA and HIV‐1: heterozygote advantage and B*35‐Cw*04 disadvantage. Science 1999;283:1748‐1752.
Patel K, Norris S, Lebeck L, Feng A, Clare M, Pianko S, et al. HLA class I allelic diversity and progression of fibrosis in patients with chronic hepatitis C. Hepatology 2006;43:241‐249.
Nitschke K, Luxenburger H, Kiraithe MM, Thimme R, Neumann‐Haefelin C. CD8+ T‐cell responses in hepatitis B and C: the (HLA‐) A, B, and C of hepatitis B and C. Dig Dis 2016;34:396‐409.
Liang TJ, Block TM, McMahon BJ, Ghany MG, Urban S, Guo J‐T, et al. Present and future therapies of hepatitis B: from discovery to cure. Hepatology 2015;62:1893‐1908.
Baumert TF, Fauvelle C, Chen DY, Lauer GM. A prophylactic hepatitis C virus vaccine: a distant peak still worth climbing. J Hepatol 2014;61:S34‐S44.
Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH, et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003;77:68‐76.
Lechner F, Wong DKH, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000;191:1499‐1512.
Pérarnau B, Saron M‐F, San Martin BR, Bervas N, Ong H, Soloski MJ, et al. Single H2Kb, H2Db and double H2KbDb knockout mice: peripheral CD8+ T cell repertoire and anti‐lymphocytic choriomeningitis virus cytolytic responses. Eur J Immunol 1999;29:1243‐1252.
Zinkernagel RM, Haenseler E, Leist T, Cerny A, Hengartner H, Althage A. T cell‐mediated hepatitis in mice infected with lymphocytic choriomeningitis virus. Liver cell destruction by H‐2 class I‐restricted virus‐specific cytotoxic T cells as a physiological correlate of the 51Cr‐release assay? J Exp Med 1986;164:1075‐1092.
Lang PA, Recher M, Haussinger D, Lang KS. Genes determining the course of virus persistence in the liver: lessons from murine infection with lymphocytic choriomeningitis virus. Cell Physiol Biochem 2010;26:263‐272.
Masopust D, Murali‐Krishna K, Ahmed R. Quantitating the magnitude of the lymphocytic choriomeningitis virus‐specific CD8 T‐cell response: it is even bigger than we thought. J Virol 2007;81:2002‐2011.
Lang PA, Contaldo C, Georgiev P, El‐Badry AM, Recher M, Kurrer M, et al. Aggravation of viral hepatitis by platelet‐derived serotonin. Nat Med 2008;14:756‐761.
Xu H, Grusdat M, Pandyra A, Polz R, Huang J, Sharma P, et al. Type I interferon protects antiviral CD8+ T cells from NK cell cytotoxicity. Immunity 2014;40:949‐960.
Gautheron J, Gores GJ, Rodrigues CMP. Lytic cell death in metabolic liver disease. J Hepatol 2020;73:394‐408.
Iwamoto N, Ito H, Ando K, Ishikawa T, Hara A, Taguchi A, et al. Upregulation of indoleamine 2,3‐dioxygenase in hepatocyte during acute hepatitis caused by hepatitis B virus‐specific cytotoxic T lymphocytes in vivo. Liver Int 2009;29:277‐283.
Rua R, Lee JY, Silva AB, Swafford IS, Maric D, Johnson KR, et al. Infection drives meningeal engraftment by inflammatory monocytes that impairs CNS immunity. Nat Immunol 2019;20:407‐419.
Wohlleber D, Kashkar H, Gärtner K, Frings M, Odenthal M, Hegenbarth S, et al. TNF‐induced target cell killing by CTL activated through cross‐presentation. Cell Rep 2012;2:478‐487.
Guidotti L, Inverso D, Sironi L, Di Lucia P, Fioravanti J, Ganzer L, et al. Immunosurveillance of the liver by intravascular effector CD8(+) T cells. Cell 2015;161:486‐500.
Lakhani SA, Masud A, Kuida K, Porter GA, Booth CJ, Mehal WZ, et al. Caspases 3 and 7: key mediators of mitochondrial events of apoptosis. Science 2006;311:847‐851.
Brenner D, Blaser H, Mak TW. Regulation of tumour necrosis factor signalling: live or let die. Nat Rev Immunol 2015;15:362‐374.
Karki R, Sharma BR, Tuladhar S, Williams EP, Zalduondo L, Samir P, et al. COVID‐19 cytokines and the hyperactive immune response: synergism of TNF‐alpha and IFN‐gamma in triggering inflammation, tissue damage, and death. bioRxiv 2020.
Jordan MB, Hildeman D, Kappler J, Marrack P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood 2004;104:735‐743.
Lang PA, Lang KS, Xu HC, Grusdat M, Parish IA, Recher M, et al. Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8+ T‐cell immunity. Proc Natl Acad Sci U S A 2012;109:1210‐1215.
Waggoner SN, Cornberg M, Selin LK, Welsh RM. Natural killer cells act as rheostats modulating antiviral T cells. Nature 2011;481:394‐398.
Cook KD, Whitmire JK. The depletion of NK cells prevents T cell exhaustion to efficiently control disseminating virus infection. J Immunol 2013;190:641‐649.
Zimmer J, Andres E, Donato L, Hanau D, Hentges F, de la Salle H. Clinical and immunological aspects of HLA class I deficiency. QJM 2005;98:719‐727.
Boni C, Lampertico P, Talamona L, Giuberti T, Invernizzi F, Barili V, et al. Natural killer cell phenotype modulation and natural killer/T‐cell interplay in nucleos(t)ide analogue‐treated hepatitis e antigen‐negative patients with chronic hepatitis B. Hepatology 2015;62:1697‐1709.
Peppa D, Gill US, Reynolds G, Easom NJW, Pallett LJ, Schurich A, et al. Up‐regulation of a death receptor renders antiviral T cells susceptible to NK cell‐mediated deletion. J Exp Med 2013;210:99‐114.
Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, Astemborski J, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004;305:872‐874.
Seich Al Basatena NK, Macnamara A, Vine AM, Thio CL, Astemborski J, Usuku K, et al. KIR2DL2 enhances protective and detrimental HLA class I‐mediated immunity in chronic viral infection. PLoS Pathog 2011;7:e1002270.